Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns
Author(s) -
A. Rose Bran,
Anupama Reddy,
Michael Seiler,
A. Arreola,
Dominic T. Moore,
Raj S. Pruthi,
Eric Wallen,
Matthew E. Nielsen,
Hao Liu,
Katherine L. Nathanson,
Börje Ljungberg,
Hongjuan Zhao,
James D. Brooks,
Shridar Ganesan,
Gyan Bhanot,
W. Kimryn Rathmell
Publication year - 2010
Publication title -
genes and cancer
Language(s) - English
Resource type - Journals
eISSN - 1947-6027
pISSN - 1947-6019
DOI - 10.1177/1947601909359929
Subject(s) - clear cell renal cell carcinoma , computational biology , renal cell carcinoma , univariate , schema (genetic algorithms) , multivariate analysis , gene expression profiling , survival analysis , bioinformatics , biology , gene , multivariate statistics , medicine , gene expression , oncology , computer science , machine learning , genetics
Clear cell renal cell carcinoma (ccRCC) is the predominant RCC subtype, but even within this classification, the natural history is heterogeneous and difficult to predict. A sophisticated understanding of the molecular features most discriminatory for the underlying tumor heterogeneity should be predicated on identifiable and biologically meaningful patterns of gene expression. Gene expression microarray data were analyzed using software that implements iterative unsupervised consensus clustering algorithms to identify the optimal molecular subclasses, without clinical or other classifying information. ConsensusCluster analysis identified two distinct subtypes of ccRCC within the training set, designated clear cell type A (ccA) and B (ccB). Based on the core tumors, or most well-defined arrays, in each subtype, logical analysis of data (LAD) defined a small, highly predictive gene set that could then be used to classify additional tumors individually. The subclasses were corroborated in a validation data set of 177 tumors and analyzed for clinical outcome. Based on individual tumor assignment, tumors designated ccA have markedly improved disease-specific survival compared to ccB (median survival of 8.6 vs 2.0 years, P = 0.002). Analyzed by both univariate and multivariate analysis, the classification schema was independently associated with survival. Using patterns of gene expression based on a defined gene set, ccRCC was classified into two robust subclasses based on inherent molecular features that ultimately correspond to marked differences in clinical outcome. This classification schema thus provides a molecular stratification applicable to individual tumors that has implications to influence treatment decisions, define biological mechanisms involved in ccRCC tumor progression, and direct future drug discovery.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom